Reference

CEM/CMO/2022/003

Name

COVID therapeutic alert – palivizumab passive immunisation against Respiratory Syncytial Virus (RSV) in at risk pre-term infants

Categories

Scottish Government Drug Alerts

Organization

Scottish Government Health and Social Care Directorates

Keywords

NHS SCOTLAND DRUGS SAFETY RISKS PHARMACEUTICAL INDUSTRY DRUG THERAPY PHARMACEUTICAL SERVICES

Description

CMO letter about an update to the UK rapid policy statement published in June 2021 which extended the eligibility criteria for passive immunisation with palivizumab to a further group of at-risk infants for dissemination to relevant healthcare professionals for onward transmission.

Contact Name

Contact Email

Contact Address

Scottish Government<br> St Andrew’s House<br> Regent Road<br> Edinburgh EH1 3DG.

Contact Phone

Created

2022-01-28 00:00:00

Download URL